{"id":1572,"date":"2016-10-05T14:49:43","date_gmt":"2016-10-05T11:49:43","guid":{"rendered":"https:\/\/www.womansprevention.gr\/en\/aptima-hpv-adenokarkinoma\/"},"modified":"2016-10-07T15:21:00","modified_gmt":"2016-10-07T12:21:00","slug":"aptima-hpv-test-adenocarcinoma","status":"publish","type":"page","link":"https:\/\/www.womansprevention.gr\/en\/aptima-hpv-test-adenocarcinoma\/","title":{"rendered":"Aptima HPV Test & Adenocarcinoma"},"content":{"rendered":"

\u2015 Aptima HPV Test<\/strong><\/p>\n

HPV is responsible to a great extend (>99%) for cervical cancer1-3<\/sup>.<\/p>\n

Aptima HPV Test detects high risk HPV types by aiming at the area \u03956\/\u03957 of the virus mRNA 4<\/sup>.\u00a0 Research has proven that detecting area \u03956\/\u03957 of the virus mRNA suggests the presence of an active HPV infection 5,6<\/sup>. A large number of clinical studies performed on more than 50,000 women have proven that Aptima HPV Test has the same high sensitivity and better specificity than HPV DNA Tests 4,7-21<\/sup>.<\/p>\n

Aptima HPV Test detects women who run a high risk to suffer from cervical cancer and due to its high sensitivity it minimizes false negative results.<\/p>\n

On the other hand, false positive results may lead to overtreatment.\u00a0 Aptima HPV Test offers improved specificity, therefore reduces significantly the number of false positive results.\u00a0\u00a0 In the CLEAR study, Aptima HPV Test reduced by 24% the number of false positive results 4<\/sup>.<\/p>\n

\n

\u2015 Aptima HPV 16 18\/45 Test <\/strong><\/p>\n

Recent data have shown that the incidence of cervical cancer has reduced during the last 50 years, while, on the same time period, cervical adenocarcinoma population has a 32% increase 22<\/sup>.<\/p>\n

Aptima HPV 16 18\/45 was designed in order to detect adenocarcinoma.\u00a0 Clinical studies have shown that up to 94% cases of cervical adenocarcinoma are connected to types 16,18 or 45. More specifically, 12% of those cases are connected with type 45 of the virus 22<\/sup>.<\/p>\n

It is a fact, though, that type 45 is not only common on all adenocarcinomas, but also that it is the third more frequent type in all invasive types of cervical cancer, as studies have shown 23-24<\/sup>.<\/p>\n

Therefore, detecting type 45 of the virus with the help of Aptima 16 18\/45 Test makes possible to detect more women who run an increased risk to suffer from cervical cancer 23-24<\/sup>.<\/p>\n

\"aptimahpv\"<\/p>\n

\n

Sources<\/p>\n

1\u00a0 Doorbar, J. Clin Sci (Lond). 2006; 110(5):525-41.
\n2\u00a0 Monsonego J., et al. Int J Cancer. 2004; 108(3):329-33. Erratum in: Int J Cancer. 108(6):945.
\n3\u00a0 Walboomers, J. M. J Pathol. 1999; 189:12-19.
\n4\u00a0 Aptima\u00ae HPV Assay package insert #503789 Rev A 2013.
\n5\u00a0 Tinelli A, et al. Curr Pharm Biotechnol. 2009 Dec;10(8):767-71
\n6\u00a0 Cuschieri K, et al. J Med Virol. 2004 May;73(1):65-70
\n7\u00a0 Szarewski A, et al. Cancer Epidimiol Biomarkers Prev. 2008; 17(11): 3033-42
\n8\u00a0 Dockter J, et al. J Clin Virol. 2009; 45(S1): S55-S61
\n9\u00a0 Ruschenbach M, et al. Gynecol Oncol. 2010; 119(1): 98-105.
\n10\u00a0 Clad A, et al. J Clin Microbiol. 2011; Mar;49(3):1071-6.
\n11\u00a0 Ratnam S, et al. J Clin Micro. 2011; (49(2): 557-64
\n12\u00a0 Ovestad I, et al. Gynecol Oncol. 2011; 123(2): 278-283
\n13\u00a0 Szarewski A, et al. J Clin Micro. 2012; 50(6): 1867-73
\n14\u00a0 Eaton B, et al.. Poster presented at IPV 2012.
\n15\u00a0 Cushieri K, et al. J Clin Virol 2014, 59: 104-108.
\n16\u00a0 Cubie HA, et al. J Clin Pathol 2014, 67:458\u2013463.
\n17\u00a0 Wu R, et al. Intl J Gyn Cancer. 2010; 20(8): 1411-14
\n18\u00a0 Monsonego J, et al. Intl J Cancer. 2011; 129: 691-701
\n19\u00a0 Infner,T, et al. Comparison of Aptima and HC2 in a routine screening trial in Germany with follow up [abstract].
\n20\u00a0 Cuzick, J et al. Br J Cancer. 2013 March 5; 108(4): 908\u2013913.
\n21\u00a0 Nieves L, et al. Int J Gynecol Cancer 2013, 23:513-518.
\n22\u00a0 Saslow et al. Am J Clin Pathol. 2012; 137(4):516-42.
\n23\u00a0 de Sanjose et al. Lancet 2010;11:1048-1056
\n24\u00a0 Guan et al. Intl J Cancer 2012;131:2349-2359
\n 
\nSee more at: http:\/\/www.hologic.com\/products\/clinician-diagnostic-solutions\/cervical-health\/aptima-hpv-tests#sthash.YqKKCo0W.dpuf<\/a><\/p><\/blockquote>\n

\n","protected":false},"excerpt":{"rendered":"

\u2015 Aptima HPV Test HPV is responsible to a great extend (>99%) for cervical cancer1-3. Aptima HPV Test detects high risk HPV types by aiming at the area \u03956\/\u03957 of the virus mRNA 4.\u00a0 Research has proven that detecting area \u03956\/\u03957 of the virus mRNA suggests the presence of an active HPV infection 5,6. A […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-1572","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.womansprevention.gr\/en\/wp-json\/wp\/v2\/pages\/1572","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.womansprevention.gr\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.womansprevention.gr\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.womansprevention.gr\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.womansprevention.gr\/en\/wp-json\/wp\/v2\/comments?post=1572"}],"version-history":[{"count":0,"href":"https:\/\/www.womansprevention.gr\/en\/wp-json\/wp\/v2\/pages\/1572\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.womansprevention.gr\/en\/wp-json\/wp\/v2\/media?parent=1572"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}